Mesentech is developing innovative drugs that can selectively deliver drugs to the bone in order to rebuild bone lost to disease, trauma, and to reverse osteoporosis.

Mesentech was founded by Dr. Robert Young,  who led teams that discovered SingulAir, Vioxx, Arcoxia, ondanacatib, among others while leading medicinal chemistry at Merck. Mesentech lead compound is MES—1007, a bone-targeted prodrug of a prostaglandin mimetic that has the potential to reverse bone-loss caused by diseases such as Duchenne muscular dystrophy and osteoporosis. 

Mesentech is also leveraging bi-specific drug conjugate technology to develop new drugs for hematological and gastrointestinal diseases.

Founded in 2006, Mesentech in based in Vancouver, Canada.